Pfizer EBIT 2012-2026 | PFE
Pfizer annual and quarterly EBIT history from 2012 to 2026. EBIT can be defined as earnings before interest and taxes.
- Pfizer EBIT for the quarter ending March 31, 2026 was $4.032B, a 7.87% increase year-over-year.
- Pfizer EBIT for the twelve months ending March 31, 2026 was $14.538B, a 20.68% increase year-over-year.
- Pfizer 2025 annual EBIT was $14.244B, a 14.77% increase from 2024.
- Pfizer 2024 annual EBIT was $12.411B, a 870.37% increase from 2023.
- Pfizer 2023 annual EBIT was $1.279B, a 96.43% decline from 2022.
|
Pfizer Annual EBIT (Millions of US $) |
|
|---|---|
| 2025 | $14,244 |
| 2024 | $12,411 |
| 2023 | $1,279 |
| 2022 | $35,789 |
| 2021 | $19,433 |
| 2020 | $8,250 |
| 2019 | $6,710 |
| 2018 | $5,672 |
| 2017 | $13,722 |
| 2016 | $12,145 |
| 2015 | $11,824 |
| 2014 | $13,249 |
| 2013 | $15,184 |
| 2012 | $15,264 |
| 2011 | $13,967 |
|
Pfizer Quarterly EBIT (Millions of US $) |
|
|---|---|
| 2026-03-31 | $4,032 |
| 2025-12-31 | $2,872 |
| 2025-09-30 | $3,851 |
| 2025-06-30 | $3,783 |
| 2025-03-31 | $3,738 |
| 2024-12-31 | $2,347 |
| 2024-09-30 | $4,959 |
| 2024-06-30 | $1,003 |
| 2024-03-31 | $4,102 |
| 2023-12-31 | $-4,288 |
| 2023-09-30 | $-3,171 |
| 2023-06-30 | $2,194 |
| 2023-03-31 | $6,544 |
| 2022-12-31 | $5,226 |
| 2022-09-30 | $8,943 |
| 2022-06-30 | $12,219 |
| 2022-03-31 | $9,401 |
| 2021-12-31 | $2,991 |
| 2021-09-30 | $6,147 |
| 2021-06-30 | $5,606 |
| 2021-03-31 | $4,689 |
| 2020-12-31 | $703 |
| 2020-09-30 | $2,448 |
| 2020-06-30 | $2,072 |
| 2020-03-31 | $3,027 |
| 2019-12-31 | $-4,928 |
| 2019-09-30 | $2,958 |
| 2019-06-30 | $4,266 |
| 2019-03-31 | $4,414 |
| 2018-12-31 | $-6,017 |
| 2018-09-30 | $3,764 |
| 2018-06-30 | $3,976 |
| 2018-03-31 | $3,949 |
| 2017-12-31 | $2,307 |
| 2017-09-30 | $3,664 |
| 2017-06-30 | $3,741 |
| 2017-03-31 | $4,010 |
| 2016-12-31 | $1,756 |
| 2016-09-30 | $3,021 |
| 2016-06-30 | $3,477 |
| 2016-03-31 | $3,891 |
| 2015-12-31 | $1,834 |
| 2015-09-30 | $3,358 |
| 2015-06-30 | $3,595 |
| 2015-03-31 | $3,037 |
| 2014-12-31 | $2,147 |
| 2014-09-30 | $3,682 |
| 2014-06-30 | $3,950 |
| 2014-03-31 | $3,470 |
| 2013-12-31 | $3,043 |
| 2013-09-30 | $3,984 |
| 2013-06-30 | $4,287 |
| 2013-03-31 | $3,870 |
| 2012-12-31 | $2,560 |
| 2012-09-30 | $3,743 |
| 2012-06-30 | $4,868 |
| 2012-03-31 | $4,093 |
| 2011-12-31 | $1,913 |
| 2011-09-30 | $4,088 |
| 2011-06-30 | $4,021 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |